1)Tozer K, Roller AB, Chong LP et al:Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 120:2029-2034, 2013
2)Lee WK, Iida T, Ogura Y et al:Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study:a randomized clinical trial. JAMA Ophthalmol 136:786-793, 2018
3)Sakai T, Kato N, Kubota M et al:Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:1565-1571, 2017
4)髙橋寛二・石橋達朗・小椋祐一郎・他:厚生労働省網膜脈絡膜・視神経萎縮症調査研究班加齢黄斑変性診断基準作成ワーキンググループ:加齢黄斑変性の分類と診断基準.日眼会誌112:1076-1084,2008
5)日本ポリープ状脈絡膜血管症研究会:ポリープ状脈絡膜血管症の診断基準.日眼会誌109:417-427,2005
6)Yanagi Y, Ting DSW, Ng WY et al:Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. Retina 38:1509-1517, 2018
7)Brown DM, Regillo CD:Anti-VEGF agents in the treatment of neovascular age-realted macular degeneration:applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627-637, 2007
8)Ting DSW, Yanagi Y, Agrawal R et al:Choroidal remodeling in age-related macular degenelration and polypoidal choroidal vasculopathy:a 12-month prospective study, Sci Rep 7:7868, 2017